Terpstra W F, May J F, Smit A J, de Graeff P A, Havinga T K, van den Veur E, Schuurman F H, Meyboom-de Jong B, Crijns H J
Department of Cardiology, University Hospital Groningen, The Netherlands.
J Hypertens. 2001 Feb;19(2):303-9. doi: 10.1097/00004872-200102000-00018.
To compare the effects of a calcium antagonist (amlodipine) and an angiotensin converting enzyme inhibitor (lisinopril) on left ventricular mass and diastolic function in elderly, previously untreated hypertensives.
A double-blind randomized parallel group trial. Effects of amlodipine and lisinopril on left ventricular mass and diastolic function (E/A Ratio) (The ELVERA trial).
Rural northern Netherlands: population screening new diagnosed hypertensive subjects.
The study population comprised 166 newly diagnosed hypertensive (aged 60-75) with diastolic blood pressure between 95-115 mmHg and/or systolic blood pressure between 160-220 mmHg.
Patients were randomly allocated to receive 5-10 mg amlodipine or 10-20 mg lisinopril for 2 years.
Prior and after 1 and 2 years of treatment left ventricular mass, indexed by body surface (LVMI) was estimated by 2-D mode echocardiography according to Devereux with use of Penn convention. Early to atrial filling ratio (E/A) was assessed by transmitral flow. Change from baseline of LVMI and E/A ratio was evaluated by repeated measurement analysis of the treatment effect in an intention-to-treat analysis.
Both amlodipine and lisinopril led to equivalent reduction in systolic and diastolic blood pressure. At the end of the study the amlodipine group led to LVMI decrease by 21.8 g/m < or = [95% confidence interval (CI), 18.3-25.3] and E/A ratio increased by 0.08 (95% CI, 0.05-0.11). In the lisinopril group LVMI decreased by 22.4 g/m < or = (95%, CI, 19.0-25.8) and E/A ratio increased by 0.07 (95% CI, 0.04-0.10). No statistically significant differences were found in changes in LVMI and E/A ratio between amlodipine and lisinopril.
A long-term study, the ELVERA trial proves that amlodipine and lisinopril reduce left ventricular mass and improve diastolic function to a similar extent in elderly newly diagnosed hypertensive patients.
比较钙拮抗剂(氨氯地平)和血管紧张素转换酶抑制剂(赖诺普利)对老年初治高血压患者左心室质量和舒张功能的影响。
双盲随机平行组试验。氨氯地平和赖诺普利对左心室质量和舒张功能(E/A比值)的影响(ELVERA试验)。
荷兰北部农村:对新诊断高血压患者进行人群筛查。
研究人群包括166例新诊断的高血压患者(年龄60 - 75岁),舒张压在95 - 115 mmHg之间和/或收缩压在160 - 220 mmHg之间。
患者被随机分配接受5 - 10 mg氨氯地平或10 - 20 mg赖诺普利治疗2年。
治疗前、治疗1年和2年后,根据Devereux采用Penn惯例通过二维超声心动图评估以体表面积为指数的左心室质量(LVMI)。通过二尖瓣血流评估早期与心房充盈比值(E/A)。在意向性分析中,通过重复测量治疗效果分析评估LVMI和E/A比值相对于基线的变化。
氨氯地平和赖诺普利均使收缩压和舒张压等效降低。在研究结束时,氨氯地平组使LVMI降低21.8 g/m²(95%置信区间[CI],18.3 - 25.3),E/A比值增加0.08(95% CI,0.05 - 0.11)。在赖诺普利组,LVMI降低22.4 g/m²(95% CI,19.0 - 25.8),E/A比值增加0.07(95% CI,0.04 - 0.10)。氨氯地平和赖诺普利之间在LVMI和E/A比值变化方面未发现统计学显著差异。
一项长期研究,ELVERA试验证明氨氯地平和赖诺普利在老年新诊断高血压患者中降低左心室质量和改善舒张功能的程度相似。